GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 11, 2024 DALLAS, Nov. 11, 2024 — GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

GLP-1 agonist drugs like Ozempic, and SLGT2 inhibitor drugs like Jardiance have been linked with a lower risk of a second ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

New classes of drugs like the SGLT-2 Inhibitors and GLP-1 Receptor Agonists  have tremendous potential for managing the blood ...

"The findings from these target trial emulations indicate that SGLT-2 inhibitors could be a valuable addition to existing ...

(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce ...